# Isovitexin (Apigenin-6-C-glucoside)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/isovitexin-apigenin-6-c-glucoside
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Apigenin-6-C-glucoside, 6-C-glucosylapigenin, Isovitexin (IV), Homovitexin, CAS 29702-25-8

## Overview

Isovitexin is a C-glycosyl flavone that exerts anxiolytic, [anti-inflammatory](/ingredients/condition/inflammation), and antioxidant effects by inhibiting NF-κB and MAPK signaling pathways, targeting SHP2 phosphatase in T cells, and activating the Nrf2/HO-1 antioxidant axis. Preclinical animal studies demonstrate significant reductions in inflammatory markers and [oxidative stress](/ingredients/condition/antioxidant) parameters at doses of 10–20 mg/kg, though no human clinical trials have yet been completed to establish efficacy or safe dosing in humans.

## Health Benefits

- **Anti-Inflammatory Activity**: Isovitexin suppresses NF-κB nuclear translocation and MAPK phosphorylation, reducing production of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including TNF-α, IL-6, IL-2, IFN-γ, IL-17A, iNOS, and COX-2 in both in vitro and murine models of acute inflammation.
- **Anxiolytic and [Neuroprotective Effect](/ingredients/condition/cognitive)s**: In rodent behavioral models, isovitexin demonstrates anxiolytic properties potentially linked to modulation of GABAergic signaling and suppression of neuroinflammatory mediators, positioning it as a candidate for stress-related disorders.
- **Antioxidant Defense Enhancement**: By upregulating the Nrf2/HO-1 pathway, isovitexin reduces [reactive oxygen species](/ingredients/condition/antioxidant) (ROS), malondialdehyde (MDA), and myeloperoxidase (MPO) while simultaneously increasing glutathione (GSH) and superoxide dismutase (SOD) activity in lung and hepatic tissues.
- **Acute Lung Injury Protection**: In LPS-induced acute lung injury (ALI) mouse models, isovitexin (10–20 mg/kg) significantly decreased TNF-α and IL-6 levels in bronchoalveolar lavage fluid (BALF), improved endothelial barrier integrity, and reduced histopathological lung damage by downregulating ICAM-1 and VCAM-1 expression.
- **Contact Dermatitis Suppression**: In GA-induced contact dermatitis murine models, isovitexin reduced ear swelling, inflammatory cell infiltration, splenomegaly, and serum cytokine levels comparably to dexamethasone, without the associated weight loss or leukocyte toxicity of corticosteroid treatment.
- **[Hepatoprotective](/ingredients/condition/detox) Properties**: Isovitexin modulates N6-methyladenosine (m6A) RNA modifications on PTEN and BiP mRNA, upregulating PI3K/Akt/mTOR signaling to suppress endoplasmic reticulum (ER) stress and hepatic inflammation in preclinical liver injury models.
- **T-Cell [Immunomodulat](/ingredients/condition/immune-support)ion**: Isovitexin targets SHP2 phosphatase in T lymphocytes, restraining STAT3 and STAT6 phosphorylation to inhibit aberrant T-cell proliferation and apoptosis resistance, an effect confirmed by reversal with the SHP2 inhibitor SHP099 and validated through molecular docking analyses.

## Mechanism of Action

Isovitexin inhibits the NF-κB signaling pathway by preventing IκB degradation and blocking p65 nuclear translocation, while simultaneously reducing phosphorylation of key MAPK proteins (ERK, JNK, p38), thereby attenuating transcription of pro-inflammatory genes encoding TNF-α, IL-6, COX-2, and iNOS. In T lymphocytes, the compound directly engages SHP2 tyrosine phosphatase, suppressing downstream STAT3 and STAT6 phosphorylation to restrain [T-cell](/ingredients/condition/immune-support) hyperactivation and cytokine-driven [inflammation](/ingredients/condition/inflammation). Concurrently, isovitexin activates the Keap1-Nrf2-ARE [antioxidant](/ingredients/condition/antioxidant) response pathway, upregulating heme oxygenase-1 (HO-1) expression to neutralize ROS and restore endothelial barrier function through reduced ICAM-1 and VCAM-1 surface expression. In hepatic contexts, isovitexin influences epitranscriptomic regulation by modulating m6A methylation on PTEN and BiP transcripts, enhancing PI3K/Akt/mTOR pathway activity to mitigate ER stress-induced apoptosis and inflammatory cascades.

## Clinical Summary

No human clinical trials investigating isovitexin as a standalone intervention have been completed or published; all current clinical-context data derive from animal models and cell-based assays. Murine studies of acute lung injury and contact dermatitis demonstrate dose-dependent reductions in [inflammatory](/ingredients/condition/inflammation) cytokine panels (TNF-α, IL-6, IL-17A) and tissue damage scores at 10–20 mg/kg, with an apparently favorable tolerability profile compared to dexamethasone controls, though these findings cannot be directly extrapolated to human dosing. Effect sizes and statistical parameters are underreported in available literature, limiting meta-analytic synthesis. Confidence in clinical efficacy remains very low due to the complete absence of human pharmacokinetic data, bioavailability studies, or safety trials, and isovitexin should be considered an early-stage investigational compound rather than a clinically validated intervention.

## Nutritional Profile

Isovitexin (apigenin-6-C-glucoside, C₂₁H₂₀O₁₀, MW 432.38) is a C-glycosylated flavone, not a macronutrient source. It occurs naturally in passionflower (Passiflora incarnata) at ~0.02–0.10% dry weight, bamboo leaves (Phyllostachys spp.) at ~0.5–2.0 mg/g, hawthorn (Crataegus spp.) berries, mung bean (Vigna radiata) sprouts, and rice hull extracts. The C-glycosidic bond at the 6-position renders it resistant to acid hydrolysis and gut glycosidase cleavage, resulting in slower but more sustained absorption compared to O-glycosides. Oral bioavailability in rodent models is estimated at 8–15%, with significant first-pass [metabolism](/ingredients/condition/weight-management). Peak plasma concentrations of ~0.3–1.2 µM have been reported after oral doses of 20–50 mg/kg in rats. It is metabolized primarily via ring-fission by colonic microbiota (Bacteroides, Eubacterium) to phloroglucinol and 3-(3,4-dihydroxyphenyl)propionic acid derivatives. The intact C-glucoside can also undergo phase II conjugation (glucuronidation, sulfation) in the liver. Typical supplemental or experimental doses range from 5–50 mg in human-relevant extracts.

## Dosage & Preparation

- **Isolated Pure Compound (Research Grade)**: Used at 10–20 mg/kg body weight via intraperitoneal injection or oral gavage in murine studies; no equivalent human dose established.
- **Standardized Plant Extracts**: Isovitexin is present in mung bean coat extracts (CLE), passionflower extracts (Passiflora incarnata), and bamboo leaf flavonoid extracts, though standardization specifically to isovitexin content is not yet commercially routine.
- **Passionflower Supplements**: Commercial passionflower products standardized to total flavonoids (typically 3.5–4% flavonoids) contain isovitexin as a constituent alongside vitexin and orientin, with typical doses of 300–400 mg extract per serving.
- **Traditional Decoction (Mung Bean)**: Whole mung bean preparations used in traditional Chinese medicine involve boiling dried seeds or seed coats in water; exact isovitexin yield from such preparations is unquantified.
- **Timing**: No human pharmacokinetic data exist to inform optimal timing of administration; preclinical acute models use single-dose pre-treatment protocols.
- **Bioavailability Consideration**: As a C-glycoside flavone, isovitexin resists hydrolysis by intestinal glycosidases more than O-glycosides, potentially limiting aglycone liberation; gut microbiota [metabolism](/ingredients/condition/weight-management) may play a role in bioactivation, though this is uncharacterized in humans.

## Safety & Drug Interactions

In preclinical murine models, isovitexin at doses of 10–20 mg/kg showed no observable signs of toxicity, body weight loss, or gross organ pathology, and demonstrated a favorable tolerability profile relative to dexamethasone in [inflammation](/ingredients/condition/inflammation) models; however, formal toxicological studies including LD50 determination, subchronic toxicity, and genotoxicity assessments have not been comprehensively published in the available literature. No human safety data, maximum tolerated doses, or adverse event profiles have been established, and the compound should be treated as investigational with respect to human use. Theoretical drug interactions are plausible given isovitexin's modulation of CYP enzyme substrates through Nrf2 induction, as well as potential additive immunosuppressive effects when combined with corticosteroids, calcineurin inhibitors, or other [T-cell](/ingredients/condition/immune-support) targeting therapies, though these interactions have not been empirically tested. Isovitexin use during pregnancy or lactation cannot be recommended due to the complete absence of safety data in these populations; individuals with autoimmune conditions or those receiving immunosuppressive therapy should exercise particular caution.

## Scientific Research

The current body of evidence for isovitexin is exclusively preclinical, consisting of in vitro cell culture studies (RAW 264.7 macrophages, human pulmonary endothelial cells, Con A-activated T cells) and in vivo murine models, with no published human randomized controlled trials identified as of 2024. In vivo studies employ intraperitoneal or oral dosing at 10–20 mg/kg in mouse models of acute lung injury, contact dermatitis, and liver injury, reporting statistically significant reductions in [cytokine](/ingredients/condition/inflammation) levels and histopathological damage scores compared to vehicle controls, though specific p-values, sample sizes, and confidence intervals are inconsistently reported across publications. Molecular docking and enzyme inhibition assays provide mechanistic plausibility for SHP2 targeting and Nrf2 activation, lending biochemical credibility to observed in vivo effects, but translational relevance to human disease remains unestablished. The overall evidence base is rated preliminary; while mechanistic data are internally consistent, the absence of pharmacokinetic characterization in humans, standardized dosing protocols, or Phase I safety studies represents a significant gap before clinical application can be recommended.

## Historical & Cultural Context

Isovitexin as an isolated chemical entity is a product of modern phytochemical research rather than traditional medicine, having been identified and characterized primarily in the latter half of the 20th century through advances in chromatographic separation and spectroscopic identification. However, the source plants from which it is isolated carry significant traditional use histories: mung beans (Vigna radiata) have been used in Traditional Chinese Medicine (TCM) for over 2,000 years as a cooling, detoxifying food used to clear heat and reduce inflammation, and Vitex negundo has been employed in Ayurvedic and TCM traditions as an [anti-inflammatory](/ingredients/condition/inflammation) and analgesic agent. Passionflower, another isovitexin-containing plant, was used by indigenous peoples of the Americas as a sedative and anxiolytic preparation, a use that was later adopted in European phytotherapy. The modern scientific interest in isovitexin thus represents a convergence of traditional ethnopharmacological observations and contemporary molecular pharmacology, with researchers using ancestral knowledge of these plants to guide the isolation and mechanistic study of constituent flavonoids.

## Synergistic Combinations

Isovitexin pairs synergistically with **vitexin (apigenin-8-C-glucoside)**, its positional isomer found alongside it in passionflower, as the two C-glycosylflavones collectively potentiate GABAₐ receptor modulation and anxiolytic activity at combined doses of 5–15 mg each. **Chrysin (5,7-dihydroxyflavone)**, another passionflower flavone, enhances this GABAergic synergy and adds complementary [anti-inflammatory](/ingredients/condition/inflammation) action via additional COX-2 suppression. **Piperine (5–10 mg, from black pepper)** significantly improves isovitexin's oral bioavailability by inhibiting hepatic UDP-glucuronosyltransferase and CYP3A4-mediated phase II conjugation, potentially doubling plasma levels. **Curcumin (200–500 mg)** synergizes on the NF-κB/MAPK anti-inflammatory axis—curcumin blocks IKKβ upstream while isovitexin suppresses NF-κB p65 nuclear translocation, providing dual-checkpoint inhibition of pro-inflammatory cascades. **Luteolin (10–25 mg)**, a structurally related flavone, shares overlapping yet additive activity on iNOS and COX-2 suppression and may enhance [neuroprotective effect](/ingredients/condition/cognitive)s via complementary Nrf2/ARE pathway activation.

## Frequently Asked Questions

### What is isovitexin and what plants does it come from?

Isovitexin is a C-glycosyl flavone flavonoid with the chemical structure of apigenin attached to a glucose unit at the 6-position of its A-ring. It is found naturally in mung beans (Vigna radiata) seed coats, passionflower (Passiflora incarnata), Vitex negundo, bamboo leaves, and several other plant species distributed across Asia and the Mediterranean. It is structurally distinct from its isomer vitexin, which carries the glucose attachment at the 8-position.

### What does isovitexin do in the body?

Isovitexin primarily acts by inhibiting two major pro-inflammatory signaling pathways—NF-κB and MAPK—thereby reducing the production of cytokines such as TNF-α, IL-6, and IL-17A that drive inflammation and tissue damage. It also activates the Nrf2/HO-1 antioxidant pathway, increasing protective enzymes like superoxide dismutase (SOD) and glutathione (GSH) while decreasing reactive oxygen species. In T lymphocytes specifically, it targets the SHP2 phosphatase enzyme to suppress aberrant immune cell activation.

### Is there clinical evidence that isovitexin works in humans?

As of 2024, no human clinical trials investigating isovitexin as a standalone compound have been published; all available evidence comes from in vitro cell studies and mouse models of acute lung injury, contact dermatitis, and liver injury. While the preclinical data show consistent anti-inflammatory and antioxidant effects at doses of 10–20 mg/kg in mice, these findings cannot be directly translated to humans without pharmacokinetic and safety studies. Isovitexin should currently be regarded as a preliminary-evidence compound with promising but unconfirmed human relevance.

### What is the recommended dose of isovitexin for humans?

No standardized human dose for isovitexin has been established because no clinical trials have been conducted in humans. Research in mice uses doses of 10–20 mg/kg administered intraperitoneally or orally, but direct allometric scaling to human doses is not validated without human pharmacokinetic data. Isovitexin is sometimes consumed indirectly through passionflower extracts standardized to total flavonoids (typically at 300–400 mg extract per serving), though the specific isovitexin content in such products is usually unstated.

### Is isovitexin safe, and does it interact with medications?

In animal studies, isovitexin at anti-inflammatory doses showed no observable toxicity or body weight changes, and appeared better tolerated than dexamethasone in the same inflammatory models. However, no human safety, toxicology, or drug interaction data exist. Theoretical caution is warranted with immunosuppressive drugs (e.g., corticosteroids, calcineurin inhibitors) due to overlapping T-cell modulation, and with medications metabolized via CYP enzymes that may be influenced by Nrf2 induction; consultation with a healthcare provider is advised before use.

### How does isovitexin compare to other flavonoid compounds like apigenin or vitexin?

Isovitexin is a C-glycoside form of apigenin (the parent compound) with a glucose molecule attached at the 6-carbon position, which distinguishes it from vitexin (apigenin-8-C-glucoside) and free apigenin. This C-glycosidic bond makes isovitexin more resistant to gut microbiota degradation and may provide superior bioavailability compared to O-glycoside flavonoids. While apigenin has similar anti-inflammatory mechanisms, isovitexin's glycosylation pattern may influence its absorption rate and tissue distribution differently.

### What is the bioavailability of isovitexin, and does food matrix affect how well it is absorbed?

Isovitexin's C-glycosidic linkage allows it to bypass hepatic metabolism initially and reach systemic circulation more effectively than many O-glycosides, though absolute oral bioavailability remains limited in humans. The food matrix can influence absorption through effects on gastric pH, bile salt availability, and intestinal transit time, though research specifically examining isovitexin biokinetics in fed versus fasted states is limited. Co-consumption with dietary fats and fermented foods may enhance bioavailability by supporting a beneficial gut microbiota composition.

### Which populations might benefit most from isovitexin supplementation based on current research?

Individuals with elevated inflammatory markers, anxiety-related conditions, or neuroinflammatory concerns may derive the most benefit from isovitexin, given its preclinical evidence for NF-κB suppression and anxiolytic activity in rodent models. Older adults experiencing age-related cognitive decline or chronic inflammatory conditions could be candidates, though human clinical trials remain limited. Those unable to tolerate or benefit from synthetic anxiolytics, or seeking natural neuroprotective support, represent an emerging demographic interest, but individual suitability should be assessed by a healthcare provider.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*